2° LINFOMA

Introduction to Cancer Prevention and Management Course

Overview of the Course

• The course is organized by the Ministry of Health's cancer prevention and control department, focusing on telehealth and urgent care. Participants are encouraged to stay updated on future sessions for certification requirements.

• To obtain a certificate, participants must register via a form, attend at least 80% (12 out of 15) tele-training sessions, and respond to attendance forms during each session.

Today's Topic: Lymphomas

• Dr. Oliver Raciel Rúa Fernández, an oncologist from Hospital Nacional Cayetano Heredia, presents on lymphomas, emphasizing their importance in patient treatment and timely diagnosis.

• Attendees can ask questions through chat during the presentation for clarification at the end.

Understanding Lymphomas

Definition and Types

• Lymphomas are malignant neoplasms derived from immune system cells, particularly lymphocytes; they include Hodgkin's lymphoma and non-Hodgkin's lymphoma (NHL).

• There are over 50 types of lymphomas characterized by different cellular features and clinical presentations; treatment varies accordingly. Non-Hodgkin's lymphomas are highlighted due to their higher prevalence globally.

Epidemiology

• Non-Hodgkin's lymphomas rank as the sixth most common tumor worldwide and fifth in mortality rates within certain countries; they frequently appear in diagnostic statistics.

Etiology of Lymphoma

Genetic Risk Factors

• The development of lymphoma involves individual genetic risk factors linked to specific mutations; while cancer is primarily genetic, only about 8–15% is hereditary. Most cases arise from acquired genetic alterations rather than familial transmission.

Chronic Inflammation

• Chronic inflammation is recognized as a potential cancer activator; uncontrolled inflammatory processes can lead to signaling pathways that promote cell proliferation and malignancy development. Examples include chronic gastritis leading to gastric lymphoma due to Helicobacter infection.

Immune Evasion Mechanisms

Tumor Cell Strategies

• Tumor cells often evade immune detection through various mechanisms such as producing proteins that inhibit immune responses (e.g., PD-L1), allowing them to proliferate unchecked despite immune surveillance efforts. This includes reprogramming metabolic pathways for survival under stress conditions like hypoxia or nutrient deprivation.

Carcinogenic Influences

Environmental Factors

• Exposure to known carcinogens (e.g., benzene, asbestos) contributes significantly to mutation accumulation leading to neoplastic transformations in cells over time; lifestyle factors also play a role in increasing cancer risk profiles among individuals exposed chronically without adequate protection measures against these agents.

Mechanisms Behind Lymphoma Development

Cellular Alterations

• The maturation process of lymphocytes influences which type of lymphoma may develop based on where genetic alterations occur during this maturation process—examples include Burkitt’s lymphoma arising from early-stage B-cell alterations versus more indolent forms resulting from later-stage changes in mature B-cells or plasma cells.

Risk Factors for Developing Lymphoma

Key Considerations

• Age is a significant risk factor for developing any type of cancer including lymphomas; older individuals have higher incidence rates due largely due increased longevity associated with advancements in medical technology.

Other Risk Factors:

1. Radiation Exposure: Previous radiation treatments increase risks significantly.

2. Immunosuppression: Conditions like HIV/AIDS or long-term immunosuppressive therapy elevate susceptibility.

3. Viral Infections: Certain viruses (e.g., Epstein-Barr virus, HTLV-I) have been implicated in aggressive forms of lymphoma.

4. Toxic Exposures: Occupational exposure to pesticides or other carcinogenic substances raises risks substantially.

Classification of Lymphomas

Grouping Neoplasias

• Neoplasias can be classified into B-cell neoplasms (including various subtypes like diffuse large B-cell lymphoma), T-cell neoplasms (like adult T-cell leukemia/lymphoma), highlighting differences based on aggressiveness levels observed clinically across different patient populations.

An Overview of Lymphoma Types and Clinical Presentation

Common Histological Patterns in Lymphoma

• The most common histological pattern identified is diffuse large B-cell lymphoma, present in 35.8% of patients.

• Hodgkin's disease accounts for 14% of cases, while adult T-cell lymphomas also represent a notable percentage.

Clinical Staging and Symptoms

• Over 60% of patients present with clinical stages II and III; many are hospitalized at stage IV due to severe symptoms.

• Common symptoms include lymphadenopathy and hypercalcemia, which can lead to altered consciousness and cardiac rhythm disturbances.

Specific Complications Associated with Lymphoma

• Patients may experience complications such as radicular compression, gastrointestinal hemorrhages, or airway obstruction due to large masses affecting the spinal column.

• Diffuse large B-cell lymphoma represents 30-40% of all non-Hodgkin lymphomas globally, with various subtypes based on morphological specifications and associated viruses like Epstein-Barr virus.

Molecular Characteristics and Prognosis

Aggressiveness of Subtypes

• Activated B-cell type diffuse large B-cell lymphoma has poorer progression-free survival rates even with chemotherapy treatment compared to other subtypes.

• Molecular alterations in oncogenic proteins (e.g., Sonic hedgehog, BCL2, BCL6) categorize some aggressive forms as double-hit or triple-hit lymphomas, impacting prognosis significantly.

Symptom Recognition by Healthcare Professionals

• Key symptoms include fever, night sweats, weight loss, localized tumors, headaches, malaise, and pruritus that may indicate underlying lymphoma pathology. Attention should be given if itching persists without clear cause after ruling out allergies or other conditions.

Diagnostic Approaches in Lymphoma Management

Initial Diagnostic Workup

• Essential tests include complete blood count (CBC), basic biochemistry including lactate dehydrogenase (LDH), albumin levels for treatment stratification purposes; hypercalcemia may also be indicative of lymphoma onset.

• Imaging studies such as chest X-rays or CT scans are crucial for initial evaluation; PET scans are particularly useful for staging Hodgkin's disease post-treatment response assessment.

Importance of Biopsy

• A definitive diagnosis relies heavily on biopsy results from affected tissues; this is critical before initiating chemotherapy to avoid skewed results from corticosteroid exposure during treatment initiation phases.

Staging Systems and Prognostic Scales

Ann Arbor Staging System

• The Ann Arbor classification divides lymphomas into four stages based on nodal involvement relative to the diaphragm; stage IV indicates organ involvement beyond lymph nodes which is significant for prognosis assessment.

International Prognostic Index (IPI)

• IPI scores help predict patient outcomes over five years based on factors like age, LDH levels, performance status among others; lower scores correlate with better survival rates while higher scores indicate worse prognoses.

• For instance: >70% survival at five years for low IPI versus ~26% for high IPI at diagnosis time point.

This structured overview provides a comprehensive understanding of the key concepts discussed regarding lymphoma types, clinical presentations, diagnostic approaches, molecular characteristics influencing prognosis along with staging systems utilized in clinical practice.

Tratamiento de Linfomas: Enfoques y Estrategias

Tipos de Linfomas y su Agresividad

• Los linfomas pueden ser agresivos, especialmente aquellos con expresiones moleculares como bcl2, bcl6 y mic. Estos pueden ser doble o triple expresores, lo que aumenta su agresividad.

• Oncólogos a menudo optan por esquemas de quimioterapia más intensivos para tratar linfomas agresivos, como el esquema Poch. Esto incluye la adición de fármacos como el stop óxido para mejorar la respuesta del paciente.

Esquema Estándar de Quimioterapia

• Un ejemplo es el esquema CHOP (Ciclofosfamida, Doxorrubicina, Vincristina y Prednisona), que se combina con rituximab. Este tratamiento ha mostrado resultados positivos en pacientes con linfoma difuso de células grandes.

• La radioterapia también juega un papel crucial en el tratamiento, siendo efectiva tanto como terapia definitiva en linfomas indolentes como terapia paliativa para aliviar síntomas en casos avanzados.

Pronóstico y Supervivencia

• Linfomas de crecimiento lento tienen una alta tasa de supervivencia a 10-20 años si son diagnosticados en etapas tempranas; sin embargo, los estadios clínicos 3 y 4 presentan tasas de recaída del 30 al 40%.

• Nuevas terapias están surgiendo gracias a una mejor comprensión molecular del linfoma, incluyendo tratamientos dirigidos que atacan vías específicas involucradas en la enfermedad.

Avances en Terapias

• Se han desarrollado nuevas terapias biológicas e inmunoterapias que ofrecen esperanza para pacientes con linfomas refractarios o recurrentes. Por ejemplo, las terapias CAR-T modifican los linf